Medical abortion in lactating women – low levels of mifepristone in breast milk

References

• Available online at: www.stakes.fi/FI/tilastot/aiheittain/Lisaantyminen/raskaudenkeskeytykset/ raskaudenkeskeytykset_ennakko.htm. (accessed on June 28, 2009)
   Google Scholar
• Available online at: www.socialstyrelsen.se/NR/rdonlyres/93831CA6-90A3-4755-8BCE-CD6EABCD6209/13853/200912510_rev3.pdf. (accessed on June 28, 2009)
   Google Scholar
• Henshaw RC, Naji SA, Russell IT, Templeton AA. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. BMJ. 1993;89:714–17.
   Google Scholar
• Winikoff B. Acceptability of medical abortion in early pregnancy. Fam Plann Perspect. 1995;185:142–48.
   Google Scholar
• Fiala C and Gemzell-Danielsson K. Review on medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception. 2006;74:66–8.
   PubMed Web of Science ®Google Scholar
• Berlin C, Briggs G. Drugs and chemicals in human milk. Semin Fetal Neonal Med. 2005;10:149–59.
   PubMed Web of Science ®Google Scholar
• Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol. 2006;2:947–60.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Nygren KG, Johansson ED. Megestrol acetate concentrations in plasma and milk during administration of an oral contraceptive containing 4 mg megestrol acetate to nursing women. Contraception. 1977a;16:615–24.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Nygren KG, Johansson ED. d-Norgestrel concentrations in maternal plasma, milk and child plasma during administration of oral contraceptives to nursing women. Am J Obstet Gynecol. 1977b;15:178–84.
   Google Scholar
• Truitt ST, Frazer AB, Grimes DA, Gallo MF, Schulz KF. Hormonal contraception during lactation: systematic review of randomized controlled trials. Contraception. 2003;68:233–38.
   Google Scholar
• Lähteenmäki P, Heikinheimo O, Croxatto H, Spitz I, Shoupe D, Birgerson L and Luukkainen T. Pharmacokinetics and metabolism of RU 486. J Steroid Biochem. 1987;27:859–63.
   PubMedGoogle Scholar
• Heikinheimo O, Ylikorkala O, Turpeinen U, Lahteenmaki P. Pharmacokinetics of the antiprogesterone RU486: no correlation to clinical performance of RU486. Acta Endocrinol. 1990;123:298–304.
   PubMedGoogle Scholar
• Available online at: emc.medicines.org.uk/document.aspx?documentId=617#furtherInfo. (accessed on June 28, 2009)
   Google Scholar
• Heikinheimo O, Tevilin M, Shoupe D, Croxatto H, Lähteenmäki P. Quantitation of RU486 in human plasma by HPLC and RIA after column chromatography. Contraception. 1986;34:613–24.
   PubMed Web of Science ®Google Scholar
• Hill NC, Selinger M, Ferguson J, MacKenzie IZ. Transplacental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of pregnancy. Hum Reprod. 1991;6:458–62.
   Web of Science ®Google Scholar
• Elliott CL, Brennand JE, Calder AA. The effects of mifepristone on cervical ripening and labor induction in primigravidae. Obstet Gynecol. 1998;92:804–09.
   PubMed Web of Science ®Google Scholar
• Wing DA, Fassett MJ, Mishell DR.Mifepristone for preinduction cervical ripening beyond 41 weeks' gestation: a randomized controlled trial. Obstet Gynecol. 2000;96:543–48.
   PubMed Web of Science ®Google Scholar
• Wallgren A. Breastmilk consumption of healthy full-term infants. Acta Paediatr Scand. 1944;32:778.
   Google Scholar
• Abdel-Aleem H, Villar J, Gulmezoglu AM, Mostafa SA, Youssef AA, Shokry M, Watzer B. The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration. Eur J Obstet Gynecol Reprod Biol. 2003;108:25–8.
   PubMedGoogle Scholar
• Vogel D, Burkhardt T, Rentsch K, Schwee H, Watzer B, Zimmermann R, Von Mandach U. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol. 2004;191:2168–173.
   PubMed Web of Science ®Google Scholar
• Aronsson A, Fiala C, Stephansson O, Granath F, Watzer B, Gemzell-Danielsson K. Pharmacokinetic profiles up to 12 hours after administration of vaginal, sublingual and slow release oral misoprostol. Hum Reprod. 2007;22:1912–18.
   PubMed Web of Science ®Google Scholar
• Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol Pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007;99(Suppl 2):160–67.
   Google Scholar
• Foote EF, Lee DR, Karim A, Keane WF, Halstenson CE. Disposition of misoprostol and its active metabolite in patients with normal and impaired renal function. J Clin Pharmacol. 1995;35:384–89.
   PubMed Web of Science ®Google Scholar
• Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90:88–92.
   PubMed Web of Science ®Google Scholar